Johnson & Johnson Nanobiotix S.A. Transaction History
Johnson & Johnson
- $427 Million
- Q3 2025
A detailed history of Johnson & Johnson transactions in Nanobiotix S.A. stock. As of the latest transaction made, Johnson & Johnson holds 5,623,816 shares of NBTX stock, worth $115 Million. This represents 26.6% of its overall portfolio holdings.
Number of Shares
5,623,816
Previous 5,623,816
-0.0%
Holding current value
$115 Million
Previous $26.6 Million
327.49%
% of portfolio
26.6%
Previous 8.95%
Shares
2 transactions
Others Institutions Holding NBTX
# of Institutions
12Shares Held
5.88MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY239KShares$4.89 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA10.2KShares$208,1600.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P75.36KShares$109,4760.0% of portfolio
-
Morgan Stanley New York, NY2.38KShares$48,6060.0% of portfolio
-
Ubs Group Ag2.16KShares$44,1700.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $713M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...